Replies to post #144438 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Here are some of my favorites:

1. Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin

http://cellceutix.com/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin/#sthash.4SUsIfUr.dpbs

2. Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA

http://cellceutix.com/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda/#sthash.V4lfc3Fg.dpbs

3. FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis

http://cellceutix.com/fda-grants-fast-track-designation-to-cellceutixs-brilacidin-om-for-oral-mucositis/#sthash.N7fuX10u.dpbs

4. Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients

http://cellceutix.com/assay-results-from-cellceutix-phase-1-clinical-trial-of-kevetrin-for-cancer-show-increased-p21-expression-in-67-5-of-evaluable-patients/#sthash.FBc7bDlp.dpbs

5. Cellceutix's Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer

http://cellceutix.com/cellceutixs-kevetrin-receives-fda-orphan-drug-designation-for-the-treatment-of-ovarian-cancer/#sthash.LwntEz9w.dpbs

6. Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma

http://cellceutix.com/cellceutix-receives-fda-orphan-drug-designation-for-kevetrin-for-the-treatment-of-retinoblastoma/#sthash.GeMDjiKW.dpbs

7. Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Pancreatic Cancer

http://cellceutix.com/cellceutix-receives-fda-orphan-drug-designation-for-kevetrin-for-the-treatment-of-pancreatic-cancer/#sthash.GYejM2vY.dpbs

[sox040713]

In case you forgot, here are the secondary endpoints of the Prurisol trial:

Secondary Outcome Measures:
-The Secondary efficacy endpoints are the percentage of subjects in each treatment group with:≥ 2 point improvement in IGA at 28 days [ Time Frame: 28 days ] [ Designated as safety issue: No ]
-The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥ 2 point improvement in IGA at 56 days [ Time Frame: 56 Days ] [ Designated as safety issue: No ]
-The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥1 point improvement in Scaling Score of Target Lesion at 28 days [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
-The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥1 point improvement in Scaling Score of Target Lesion at 56 days [ Time Frame: 56 Days ] [ Designated as safety issue: No ]
-The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥1 point improvement in Scaling Score of Target Lesion at 84 days [ Time Frame: 84 Days ] [ Designated as safety issue: No ]

https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=2